Caris Life Sciences (NASDAQ:CAI) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Caris Life Sciences (NASDAQ:CAI) had its price objective lifted by investment analysts at Robert W. Baird from $26.00 to $28.00 in a report issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price target would indicate a potential upside of 45.53% from the stock’s current price.

Several other analysts have also recently issued reports on CAI. Weiss Ratings reissued a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Canaccord Genuity Group upped their price objective on Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Monday, December 22nd. Evercore set a $38.00 target price on Caris Life Sciences in a research note on Monday, January 5th. Finally, Wall Street Zen cut Caris Life Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $33.50.

Caris Life Sciences Stock Up 5.1%

Shares of NASDAQ CAI opened at $19.24 on Friday. The company has a current ratio of 9.93, a quick ratio of 9.36 and a debt-to-equity ratio of 0.79. The firm has a 50 day moving average price of $24.58. Caris Life Sciences has a 52-week low of $17.15 and a 52-week high of $42.50. The stock has a market capitalization of $5.43 billion and a price-to-earnings ratio of -41.83.

Caris Life Sciences (NASDAQ:CAI) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.27. During the same period last year, the firm earned ($1.73) earnings per share. Caris Life Sciences’s revenue was up 125.4% on a year-over-year basis.

Insider Activity at Caris Life Sciences

In related news, insider Luke Thomas Power sold 62,250 shares of Caris Life Sciences stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the sale, the insider directly owned 99,571 shares in the company, valued at $2,646,597.18. This trade represents a 38.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.80% of the stock is owned by company insiders.

Institutional Trading of Caris Life Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Global Retirement Partners LLC lifted its holdings in shares of Caris Life Sciences by 99,900.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after purchasing an additional 999 shares during the last quarter. Olistico Wealth LLC acquired a new position in Caris Life Sciences during the fourth quarter worth approximately $31,000. MetLife Investment Management LLC lifted its stake in Caris Life Sciences by 84.0% in the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock valued at $45,000 after buying an additional 755 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of Caris Life Sciences in the fourth quarter valued at approximately $67,000. Finally, Federated Hermes Inc. purchased a new position in shares of Caris Life Sciences during the fourth quarter worth approximately $81,000.

Caris Life Sciences News Roundup

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Q4 earnings and revenue beat—Caris reported GAAP EPS of $0.28 (vs. ~$0.01 consensus) and Q4 revenue of roughly $292–293M, up ~125% year-over-year, showing rapid top-line recovery and a swing to profitability. This beat and margin trend support upward price action. Caris Q4 & 2025 Results
• Positive Sentiment: Interim Achieve 1 readout strongly supports Caris Detect—an internal interim analysis showed whole-genome sequencing (WGS)-based Caris Detect delivered superior sensitivity and specificity versus methylation-based approaches, a key clinical validation ahead of launch that materially de-risks the MCED (multi-cancer early detection) opportunity. This is a major near-term commercial catalyst. Achieve 1 Interim Readout
• Positive Sentiment: Baird initiates coverage with an Outperform—fresh analyst coverage with a positive rating can increase investor interest and provide incremental buy-side demand. Baird Initiates Coverage
• Positive Sentiment: Product innovation—Caris added an AI-powered breast cancer signature to its Caris Molecular Tumor Board Report, enhancing its product set for clinicians and potentially expanding clinical utility and revenue per test. AI Breast Cancer Signature
• Neutral Sentiment: FY‑2026 revenue guidance updated to ~$1.0B–$1.02B, modestly above consensus (~$995.8M); management is guiding continued high growth but investors will watch margin and cadence of MCED roll-out. 2026 Guidance
• Neutral Sentiment: Short-interest data reported is noisy/erroneous in the feed (shows zeros) and is not a meaningful signal; monitor reliable short-interest updates for potential squeezes. (no link)
• Negative Sentiment: Valuation & technical context—despite today’s pop, CAI remains below its 50‑day moving average and off its one‑year high; investors should weigh execution risk of commercializing Caris Detect, regulatory review, and the company’s path to sustained profitability. (background datapoints)

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.